{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T03:11:35Z","timestamp":1794625895188,"version":"4.9.1"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurol Belg"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s13760-026-03107-8","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T01:22:18Z","timestamp":1782436938000},"page":"1649-1670","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Diagnostic accuracy of CSF and plasma pTau-181, pTau-217, and pTau-231 for Alzheimer\u2019s disease: a diagnostic meta-analysis"],"prefix":"10.1007","volume":"126","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0347-8694","authenticated-orcid":false,"given":"Hazem E.","family":"Mohammed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed E.","family":"Haseeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Nasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Hanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Salem","family":"Abdelkader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatem","family":"Yaser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shehab","family":"Yaser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Samir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusra","family":"Arafeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Wagdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Khalafalla","family":"Darwish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"3107_CR1","doi-asserted-by":"publisher","unstructured":"Alzheimer\u2019s A (2024) Alzheimer\u2019s disease facts and figures. Alzheimer\u2019s Dement [Internet]. 2024;20:3708\u2013821. Available from: https:\/\/doi.org\/10.1002\/alz.13809","DOI":"10.1002\/alz.13809"},{"key":"3107_CR2","doi-asserted-by":"crossref","unstructured":"Sehar U, Rawat P, Reddy AP, Kopel J, Reddy PH (2022) Amyloid beta in aging and alzheimer\u2019s disease. Int J Mol Sci [Internet]. 23. Available from: https:\/\/www.mdpi.com\/1422-0067\/23\/21\/12924","DOI":"10.3390\/ijms232112924"},{"key":"3107_CR3","doi-asserted-by":"publisher","unstructured":"Alberdi A, Aztiria A, Basarab A (2016) On the early diagnosis of Alzheimer\u2019s Disease from multimodal signals: A survey. Artif Intell Med [Internet]. 71:1\u201329. Available from: https:\/\/doi.org\/10.1016\/j.artmed.2016.06.003","DOI":"10.1016\/j.artmed.2016.06.003"},{"key":"3107_CR4","doi-asserted-by":"publisher","unstructured":"Collaborators GBD (2019) A Global, regional, and national burden of diseases and injuries for adults 70 years and older: systematic analysis for the Global Burden of Disease 2019 Study. BMJ [Internet]. 2022;376:e068208. Available from: https:\/\/doi.org\/10.1136\/bmj-2021-068208","DOI":"10.1136\/bmj-2021-068208"},{"key":"3107_CR5","doi-asserted-by":"crossref","unstructured":"Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S et al (2020) Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet [Internet]. 396:413\u201346. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0140673620303676","DOI":"10.1016\/S0140-6736(20)30367-6"},{"key":"3107_CR6","doi-asserted-by":"crossref","unstructured":"Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J et al (2023) Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. J Am Med Assoc [Internet]. 330:512\u201327. Available from: https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2807533","DOI":"10.1001\/jama.2023.13239"},{"key":"3107_CR7","doi-asserted-by":"publisher","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M et al (2023) Lecanemab in early alzheimer\u2019s disease. N Engl J Med [Internet]. 388:9\u201321. Available from: http:\/\/www.nejm.orghttps:\/\/doi.org\/10.1056\/NEJMoa2212948","DOI":"10.1056\/NEJMoa2212948"},{"key":"3107_CR8","doi-asserted-by":"publisher","unstructured":"Jack CR, Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A et al (2024) Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup. Alzheimer\u2019s Dement [Internet]. 20:5143\u201369. Available from: https:\/\/doi.org\/10.1002\/alz.13859","DOI":"10.1002\/alz.13859"},{"key":"3107_CR9","doi-asserted-by":"publisher","unstructured":"Keppler JS, Conti PS (2001) A cost analysis of positron emission tomography. Am J Roentgenol [Internet]. 177:31\u201340. Available from: https:\/\/doi.org\/10.2214\/ajr.177.1.1770031","DOI":"10.2214\/ajr.177.1.1770031"},{"key":"3107_CR10","doi-asserted-by":"publisher","unstructured":"Devine CE, Mawlawi O (2010) Radiation safety with positron emission tomography and computed tomography. Semin Ultrasound CT MR [Internet]. 31:39\u201345. Available from: https:\/\/doi.org\/10.1053\/j.sult.2009.09.005","DOI":"10.1053\/j.sult.2009.09.005"},{"key":"3107_CR11","doi-asserted-by":"publisher","unstructured":"Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI (1986) Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA [Internet]. 83:4913\u20137. Available from: https:\/\/doi.org\/10.1073\/pnas.83.13.4913","DOI":"10.1073\/pnas.83.13.4913"},{"key":"3107_CR12","doi-asserted-by":"publisher","unstructured":"Kovacs GG, Tauopathies (2017) Handb Clin Neurol [Internet]. 145:355\u201368. Available from: https:\/\/doi.org\/10.1016\/B978-0-12-802395-2.00025-0","DOI":"10.1016\/B978-0-12-802395-2.00025-0"},{"key":"3107_CR13","doi-asserted-by":"publisher","unstructured":"Alquezar C, Arya S, Kao AW (2020) Tau Post-translational Modifications: Dynamic Transformers of Tau Function, Degradation, and Aggregation. Front Neurol [Internet]. 11:595532. Available from: https:\/\/doi.org\/10.3389\/fneur.2020.595532","DOI":"10.3389\/fneur.2020.595532"},{"key":"3107_CR14","doi-asserted-by":"crossref","unstructured":"Barth\u00e9lemy NR, Li Y, Joseph-Mathurin N, Gordon BA, Hassenstab J, Benzinger TLS et al (2020) A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer\u2019s disease. Nat Med [Internet]. 26:398\u2013407. Available from: http:\/\/www.nature.com\/articles\/s41591-020-0781-z","DOI":"10.1038\/s41591-020-0781-z"},{"key":"3107_CR15","doi-asserted-by":"publisher","unstructured":"Janelidze S, Berron D, Smith R, Strandberg O, Proctor NK, Dage JL et al (2021) Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease. JAMA Neurol [Internet]. 78:149\u201356. Available from: https:\/\/doi.org\/10.1001\/jamaneurol.2020.4201","DOI":"10.1001\/jamaneurol.2020.4201"},{"key":"3107_CR16","doi-asserted-by":"publisher","unstructured":"Mattsson-Carlgren N, Andersson E, Janelidze S, Ossenkoppele R, Insel P, Strandberg O et al (2020) A\u03b2 deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer\u2019s disease. Sci Adv [Internet]. 6:eaaz2387. Available from: https:\/\/advances.sciencemag.org\/lookup\/doi\/https:\/\/doi.org\/10.1126\/sciadv.aaz2387","DOI":"10.1126\/sciadv.aaz2387"},{"key":"3107_CR17","doi-asserted-by":"publisher","unstructured":"Therriault J, Vermeiren M, Servaes S, Tissot C, Ashton NJ, Benedet AL et al (2023) Association of phosphorylated tau biomarkers with amyloid positron emission tomography vs tau positron emission tomography. JAMA Neurol [Internet]. 80:188\u201399. Available from: https:\/\/doi.org\/10.1001\/jamaneurol.2022.4485","DOI":"10.1001\/jamaneurol.2022.4485"},{"key":"3107_CR18","doi-asserted-by":"publisher","unstructured":"Horie K, Barth\u00e9lemy NR, Spina S, VandeVrede L, He Y, Paterson RW et al (2022) CSF tau microtubule-binding region identifies pathological changes in primary tauopathies. Nat Med [Internet]. 28:2547\u201354. Available from: https:\/\/doi.org\/10.1038\/s41591-022-02075-9","DOI":"10.1038\/s41591-022-02075-9"},{"key":"3107_CR19","doi-asserted-by":"crossref","unstructured":"Sato C, Barth\u00e9lemy NR, Mawuenyega KG, Patterson BW, Gordon BA, Jockel-Balsarotti J et al (2018) Tau kinetics in neurons and the human central nervous system. Neuron [Internet]. 97:1284\u20131298.e7. Available from: http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896627318301363","DOI":"10.1016\/j.neuron.2018.02.015"},{"key":"3107_CR20","doi-asserted-by":"publisher","unstructured":"Lombardi G, Pancani S, Manca R, Mitolo M, Baiardi S, Massa F et al (2024) Role of Blood P-Tau Isoforms (181, 217, 231) in Predicting Conversion from MCI to Dementia Due to Alzheimer\u2019s Disease: A Review and Meta-Analysis. Int J Mol Sci [Internet]. 25. Available from: https:\/\/doi.org\/10.3390\/ijms252312916","DOI":"10.3390\/ijms252312916"},{"key":"3107_CR21","doi-asserted-by":"publisher","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372. https:\/\/doi.org\/10.1136\/bmj.n71","DOI":"10.1136\/bmj.n71"},{"key":"3107_CR22","doi-asserted-by":"publisher","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A (2016) Rayyan-a web and mobile app for systematic reviews. Syst Rev [Internet]. 5:1\u201310. Available from: https:\/\/doi.org\/10.1186\/s13643-016-0384-4","DOI":"10.1186\/s13643-016-0384-4"},{"key":"3107_CR23","doi-asserted-by":"publisher","unstructured":"Whiting PF, Rutjes AWS, Westwood ME, Mallett S, Deeks JJ, Reitsma JB et al (2011) QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med [Internet]. 155:529\u201336. Available from: https:\/\/doi.org\/10.7326\/0003-4819-155-8-201110180-00009","DOI":"10.7326\/0003-4819-155-8-201110180-00009"},{"key":"3107_CR24","doi-asserted-by":"publisher","unstructured":"Higgins JPT (2003) Measuring inconsistency in meta-analyses. BMJ [Internet]. 327:557\u201360. Available from: https:\/\/www.bmj.com\/lookup\/doi\/https:\/\/doi.org\/10.1136\/bmj.327.7414.557","DOI":"10.1136\/bmj.327.7414.557"},{"key":"3107_CR25","doi-asserted-by":"publisher","unstructured":"Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PMM (2003) The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol [Internet]. ;56:1129\u201335. Available from: https:\/\/doi.org\/10.1016\/s0895-4356(03)00177-x","DOI":"10.1016\/s0895-4356(03)00177-x"},{"key":"3107_CR26","doi-asserted-by":"publisher","unstructured":"Deeks JJ, Macaskill P, Irwig L (2005) The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol [Internet]. ;58:882\u201393. Available from: https:\/\/doi.org\/10.1016\/j.jclinepi.2005.01.016","DOI":"10.1016\/j.jclinepi.2005.01.016"},{"key":"3107_CR27","doi-asserted-by":"publisher","unstructured":"Caraguel CGB, Vanderstichel R (2013) The two-step Fagan\u2019s nomogram: ad hoc interpretation of a diagnostic test result without calculation. Evid Based Med [Internet]. 18:125\u20138. Available from: https:\/\/doi.org\/10.1136\/eb-2013-101243","DOI":"10.1136\/eb-2013-101243"},{"key":"3107_CR28","doi-asserted-by":"publisher","unstructured":"Plana MN, Arevalo-Rodriguez I, Fern\u00e1ndez-Garc\u00eda S, Soto J, Fabregate M, P\u00e9rez T et al (2022) Meta-DiSc 2.0: a web application for meta-analysis of diagnostic test accuracy data. BMC Med Res Methodol [Internet]. 22:306. Available from: https:\/\/doi.org\/10.1186\/s12874-022-01788-2","DOI":"10.1186\/s12874-022-01788-2"},{"key":"3107_CR29","doi-asserted-by":"publisher","unstructured":"Plana MN, P\u00e9rez T, Zamora J (2021) New measures improved the reporting of heterogeneity in diagnostic test accuracy reviews: a meta epidemiological study. J Clin Epidemiol [Internet]. 131:101\u201312. Available from: https:\/\/doi.org\/10.1016\/j.jclinepi.2020.11.011","DOI":"10.1016\/j.jclinepi.2020.11.011"},{"key":"3107_CR30","doi-asserted-by":"publisher","unstructured":"Zhou Y, Dendukuri N (2014) Statistics for quantifying heterogeneity in univariate and bivariate meta-analyses of binary data: the case of meta-analyses of diagnostic accuracy. Stat Med [Internet]. 33:2701\u201317. Available from: https:\/\/doi.org\/10.1002\/sim.6115","DOI":"10.1002\/sim.6115"},{"key":"3107_CR31","doi-asserted-by":"publisher","unstructured":"Sch\u00fcnemann HJ, Mustafa RA, Brozek J, Steingart KR, Leeflang M, Murad MH et al (2020) GRADE guidelines: 21 part 1. Study design, risk of bias, and indirectness in rating the certainty across a body of evidence for test accuracy. J Clin Epidemiol [Internet]. 122:129\u201341. Available from: https:\/\/doi.org\/10.1016\/j.jclinepi.2019.12.020","DOI":"10.1016\/j.jclinepi.2019.12.020"},{"key":"3107_CR32","doi-asserted-by":"publisher","unstructured":"Sch\u00fcnemann HJ, Mustafa RA, Brozek J, Steingart KR, Leeflang M, Murad MH et al (2020) GRADE guidelines: 21 part 2. Test accuracy: inconsistency, imprecision, publication bias, and other domains for rating the certainty of evidence and presenting it in evidence profiles and summary of findings tables. J Clin Epidemiol [Internet]. 122:142\u201352. Available from: https:\/\/doi.org\/10.1016\/j.jclinepi.2019.12.021","DOI":"10.1016\/j.jclinepi.2019.12.021"},{"key":"3107_CR33","unstructured":"GRADEpro [Internet] [cited 2024 Aug 18]. Available from: https:\/\/www.gradepro.org\/"},{"key":"3107_CR34","doi-asserted-by":"publisher","unstructured":"Ashton NJ, Pascoal TA, Karikari TK, Benedet AL, Lantero-Rodriguez J, Brinkmalm G et al (2021) Plasma p-tau231: a new biomarker for incipient Alzheimer\u2019s disease pathology. Acta Neuropathol [Internet]. 141:709\u201324. Available from: https:\/\/doi.org\/10.1007\/s00401-021-02275-6","DOI":"10.1007\/s00401-021-02275-6"},{"key":"3107_CR35","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1001\/archneur.59.8.1267","volume":"59","author":"K Buerger","year":"2002","unstructured":"Buerger K, Zinkowski R, Teipel SJ, Tapiola T, Arai H, Blennow K et al (2002) Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch Neurol 59:1267\u20131272","journal-title":"Arch Neurol"},{"key":"3107_CR36","doi-asserted-by":"crossref","unstructured":"Dakterzada F, Cipriani R, L\u00f3pez-Ortega R, Arias A, Riba-Llena I, Ruiz-Juli\u00e1n M et al (2024) Assessment of the correlation and diagnostic accuracy between cerebrospinal fluid and plasma Alzheimer\u2019s disease biomarkers: a comparison of the Lumipulse and Simoa platforms. Int J Mol Sci 25:4594","DOI":"10.3390\/ijms25094594"},{"key":"3107_CR37","doi-asserted-by":"publisher","first-page":"6094","DOI":"10.1002\/alz.14087","volume":"20","author":"T Dayarathna","year":"2024","unstructured":"Dayarathna T, Roseborough AD, Gomes J, Khazaee R, Silveira CRA, Borron K et al (2024) Nanoscale flow cytometry-based quantification of blood-based extracellular vesicle biomarkers distinguishes MCI and Alzheimer\u2019s disease. Alzheimer\u2019s Dement 20:6094\u20136106","journal-title":"Alzheimer\u2019s Dement"},{"key":"3107_CR38","first-page":"755","volume":"61","author":"D De Jong","year":"2006","unstructured":"De Jong D, Jansen RWMM, Kremer BPH, Verbeek MM (2006) Cerebrospinal fluid amyloid \u03b242\/phosphorylated tau ratio discriminates between Alzheimer\u2019s disease and vascular dementia. Journals Gerontol - Ser Biol Sci Med Sci 61:755\u2013758","journal-title":"Journals Gerontol - Ser Biol Sci Med Sci"},{"key":"3107_CR39","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1002\/acn3.51553","volume":"9","author":"S De Meyer","year":"2022","unstructured":"De Meyer S, Vanbrabant J, Schaeverbeke JM, Reinartz M, Luckett ES, Dupont P et al (2022) Phospho-specific plasma p-tau181 assay detects clinical as well as asymptomatic Alzheimer\u2019s disease. Ann Clin Transl Neurol 9:734\u2013746","journal-title":"Ann Clin Transl Neurol"},{"key":"3107_CR40","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.jalz.2012.06.006","volume":"9","author":"J Dumurgier","year":"2013","unstructured":"Dumurgier J, Vercruysse O, Paquet C, Bombois S, Chaulet C, Laplanche JL et al (2013) Intersite variability of CSF Alzheimer\u2019s disease biomarkers in clinical setting. Alzheimer\u2019s Dement 9:406\u2013413","journal-title":"Alzheimer\u2019s Dement"},{"key":"3107_CR41","first-page":"1","volume":"9","author":"J Goossens","year":"2017","unstructured":"Goossens J, Bjerke M, Struyfs H, Niemantsverdriet E, Somers C, Van Den Bossche T et al (2017) No added diagnostic value of non-phosphorylated tau fraction (p-taurel) in CSF as a biomarker for differential dementia diagnosis. Alzheimer\u2019s Res Ther 9:1\u20137","journal-title":"Alzheimer\u2019s Res Ther"},{"key":"3107_CR42","doi-asserted-by":"publisher","first-page":"E1229","DOI":"10.1212\/WNL.0000000000012513","volume":"97","author":"MJ Grothe","year":"2021","unstructured":"Grothe MJ, Moscoso A, Ashton NJ, Karikari TK, Lantero-Rodriguez J, Snellman A et al (2021) Associations of Fully Automated CSF and Novel Plasma Biomarkers With Alzheimer Disease Neuropathology at Autopsy. Neurology 97:E1229\u2013E1242","journal-title":"Neurology"},{"key":"3107_CR43","first-page":"292","volume":"2004","author":"K Harald Hampel","year":"2004","unstructured":"Harald Hampel K, Buerger R, Zinkowski SJ, Teipel A, Goernitz N, Andreasen M, Sjoegren J, DeBernardis D, Kerkman K, Ishiguro H, Ohno E, Vanmechelen H, Vanderstichele C, McCulloch (2004) Hans-Jur KB. Measurement of Phosphorylated Tau Epitopes in the Differential Diagnosis of Alzheimer Disease: A Comparative Cerebrospinal Fluid Study. Yearb Psychiatry Appl Ment Heal 2004:292\u2013293","journal-title":"Yearb Psychiatry Appl Ment Heal"},{"key":"3107_CR44","doi-asserted-by":"publisher","first-page":"E3026","DOI":"10.1212\/WNL.0000000000010814","volume":"95","author":"J Hanes","year":"2020","unstructured":"Hanes J, Kovac A, Kvartsberg H, Kontsekova E, Fialova L, Katina S et al (2020) Evaluation of a novel immunoassay to detect p-tau Thr217 in the CSF to distinguish Alzheimer disease from other dementias. Neurology 95:E3026\u2013E3035","journal-title":"Neurology"},{"key":"3107_CR45","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1016\/j.neurobiolaging.2005.06.005","volume":"27","author":"B Ibach","year":"2006","unstructured":"Ibach B, Binder H, Dragon M, Poljansky S, Haen E, Schmitz E et al (2006) Cerebrospinal fluid tau and \u03b2-amyloid in Alzheimer patients, disease controls and an age-matched random sample. Neurobiol Aging 27:1202\u20131211","journal-title":"Neurobiol Aging"},{"key":"3107_CR46","doi-asserted-by":"publisher","unstructured":"Janelidze S, Mattsson N, Palmqvist S, Smith R, Beach TG, Serrano GE et al (2020) Plasma P-tau181 in Alzheimer\u2019s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer\u2019s dementia. Nat Med [Internet]. 26:379\u201386. Available from: https:\/\/doi.org\/10.1038\/s41591-020-0755-1","DOI":"10.1038\/s41591-020-0755-1"},{"key":"3107_CR47","doi-asserted-by":"publisher","unstructured":"Kac PR, Gonzalez-Ortiz F, Simr\u00e9n J, Dewit N, Vanmechelen E, Zetterberg H et al (2022) Diagnostic value of serum versus plasma phospho-tau for Alzheimer\u2019s disease. Alzheimer\u2019s Res Ther [Internet]. 14:1\u201312. Available from: https:\/\/doi.org\/10.1186\/s13195-022-01011-w","DOI":"10.1186\/s13195-022-01011-w"},{"key":"3107_CR48","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1002\/alz.12236","volume":"17","author":"TK Karikari","year":"2021","unstructured":"Karikari TK, Emer\u0161i\u010d A, Vrillon A, Lantero-Rodriguez J, Ashton NJ, Kramberger MG et al (2021) Head-to-head comparison of clinical performance of CSF phospho-tau T181 and T217 biomarkers for Alzheimer\u2019s disease diagnosis. Alzheimer\u2019s Dement 17:755\u2013767","journal-title":"Alzheimer\u2019s Dement"},{"key":"3107_CR49","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.3233\/JAD-230419","volume":"96","author":"T Kawarabayashi","year":"2023","unstructured":"Kawarabayashi T, Nakamura T, Miyashita K, Segawa T, Fukamachi I, Sugawara T et al (2023) Clinical Evaluation of Cerebrospinal Fluid p217tau and Neurofilament Light Chain Levels in Patients with Alzheimer\u2019s Disease or Other Neurological Diseases. J Alzheimer\u2019s Dis 96:1623\u20131638","journal-title":"J Alzheimer\u2019s Dis"},{"key":"3107_CR50","doi-asserted-by":"crossref","unstructured":"Ki\u0111emet-Piska\u010d S, Babi\u0107 Leko M, Bla\u017eekovi\u0107 A, Langer Horvat L, Klepac N, Sonicki Z et al (2018) Evaluation of cerebrospinal fluid phosphorylated tau 231 as a biomarker in the differential diagnosis of Alzheimer\u2019s disease and vascular dementia. CNS Neurosci Ther 24:734\u2013740","DOI":"10.1111\/cns.12814"},{"key":"3107_CR51","doi-asserted-by":"publisher","unstructured":"Kim HJ, Kim H, Park D, Yoon DS, San Lee J, Hwang KS (2023) Plasma-based diagnostic and screening platform using a combination of biosensing signals in Alzheimer\u2019s disease. Biosens Bioelectron [Internet]. 230:115246. Available from: https:\/\/doi.org\/10.1016\/j.bios.2023.115246","DOI":"10.1016\/j.bios.2023.115246"},{"key":"3107_CR52","doi-asserted-by":"publisher","unstructured":"Kivis\u00e4kk P, Carlyle BC, Sweeney T, Trombetta BA, LaCasse K, El-Mufti L et al (2023) Plasma biomarkers for diagnosis of Alzheimer\u2019s disease and prediction of cognitive decline in individuals with mild cognitive impairment. Front Neurol [Internet]. 14:1069411. Available from: https:\/\/doi.org\/10.3389\/fneur.2023.1069411","DOI":"10.3389\/fneur.2023.1069411"},{"key":"3107_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/ADR-230156","volume":"8","author":"G Krishna","year":"2024","unstructured":"Krishna G, Thangaraju Sivakumar P, Dahale AB, Subramanian S (2024) Potential Utility of Plasma Biomarker Panels in Differential Diagnosis of Alzheimer\u2019s Disease. J Alzheimer\u2019s Dis Rep 8:1\u20137","journal-title":"J Alzheimer\u2019s Dis Rep"},{"key":"3107_CR54","doi-asserted-by":"publisher","first-page":"E1681","DOI":"10.1212\/WNL.0000000000012727","volume":"97","author":"A Leuzy","year":"2021","unstructured":"Leuzy A, Janelidze S, Mattsson-Carlgren N, Palmqvist S, Jacobs D, Cicognola C et al (2021) Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays. Neurology 97:E1681\u2013E1694","journal-title":"Neurology"},{"key":"3107_CR55","doi-asserted-by":"publisher","unstructured":"Ye LQ, Li XY, Zhang Y, Bin, Cheng HR, Ma Y, Chen DF et al (2020) The discriminative capacity of CSF \u03b2-amyloid 42 and Tau in neurodegenerative diseases in the Chinese population. J Neurol Sci [Internet]. 412:116756. Available from: https:\/\/doi.org\/10.1016\/j.jns.2020.116756","DOI":"10.1016\/j.jns.2020.116756"},{"key":"3107_CR56","doi-asserted-by":"crossref","unstructured":"Montoliu-Gaya L, Alosco ML, Yhang E, Tripodis Y, Sconzo D, Ally M et al (2024) Optimal blood tau species for the detection of Alzheimer\u2019s disease neuropathology: an immunoprecipitation mass spectrometry and autopsy study. Acta Neuropathol 147","DOI":"10.1007\/s00401-023-02660-3"},{"key":"3107_CR57","doi-asserted-by":"publisher","first-page":"3546","DOI":"10.1093\/brain\/awac175","volume":"145","author":"MS Morrison","year":"2022","unstructured":"Morrison MS, Aparicio HJ, Blennow K, Zetterberg H, Ashton NJ, Karikari TK et al (2022) Ante-mortem plasma phosphorylated tau (181) predicts Alzheimer\u2019s disease neuropathology and regional tau at autopsy. Brain 145:3546\u20133557","journal-title":"Brain"},{"key":"3107_CR58","first-page":"1","volume":"10","author":"RW Paterson","year":"2018","unstructured":"Paterson RW, Slattery CF, Poole T, Nicholas JM, Magdalinou NK, Toombs J et al (2018) Cerebrospinal fluid in the differential diagnosis of Alzheimer\u2019s disease: Clinical utility of an extended panel of biomarkers in a specialist cognitive clinic. Alzheimer\u2019s Res Ther 10:1\u201311","journal-title":"Alzheimer\u2019s Res Ther"},{"key":"3107_CR59","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.nrleng.2022.05.002","volume":"39","author":"A Puig-Pijoan","year":"2024","unstructured":"Puig-Pijoan A, Garc\u00eda-Escobar G, Fern\u00e1ndez-Lebrero A, Manero-Borr\u00e0s RM, S\u00e1nchez-Benavides G, Navalpotro-G\u00f3mez I et al (2024) The CORCOBIA study: Cut-off points of Alzheimer\u2019s disease CSF biomarkers in a clinical cohort. Neurol (English Ed) 39:756\u2013765","journal-title":"Neurol (English Ed"},{"key":"3107_CR60","unstructured":"Pilotto A, Parigi M, Bonzi G, Battaglio B, Ferrari E, Mensi L et al (2021) disease Department of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mo"},{"key":"3107_CR61","doi-asserted-by":"publisher","unstructured":"Lantero Rodriguez J, Karikari TK, Su\u00e1rez-Calvet M, Troakes C, King A, Emersic A et al (2020) Plasma p-tau181 accurately predicts Alzheimer\u2019s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline. Acta Neuropathol [Internet]. 140:267\u201378. Available from: https:\/\/doi.org\/10.1007\/s00401-020-02195-x","DOI":"10.1007\/s00401-020-02195-x"},{"key":"3107_CR62","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1177\/1533317513504615","volume":"28","author":"YF Shea","year":"2013","unstructured":"Shea YF, Chu LW, Zhou L, Li WM, Lin OY, Chan MNY et al (2013) Cerebrospinal fluid biomarkers of Alzheimer\u2019s disease in Chinese patients: A pilot study. Am J Alzheimers Dis Other Demen 28:769\u2013775","journal-title":"Am J Alzheimers Dis Other Demen"},{"key":"3107_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0159099","volume":"11","author":"S Shekhar","year":"2016","unstructured":"Shekhar S, Kumar R, Rai N, Kumar V, Singh K, Upadhyay AD et al (2016) Estimation of Tau and phosphorylated Tau181 in serum of Alzheimer\u2019s disease and mild cognitive impairment patients. PLoS ONE 11:1\u201310","journal-title":"PLoS ONE"},{"key":"3107_CR64","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1002\/alz.12283","volume":"17","author":"J Simr\u00e9n","year":"2021","unstructured":"Simr\u00e9n J, Leuzy A, Karikari TK, Hye A, Benedet AL, Lantero-Rodriguez J et al (2021) The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer\u2019s disease. Alzheimer\u2019s Dement 17:1145\u20131156","journal-title":"Alzheimer\u2019s Dement"},{"key":"3107_CR65","doi-asserted-by":"publisher","first-page":"383","DOI":"10.3233\/JAD-151097","volume":"54","author":"C Somers","year":"2016","unstructured":"Somers C, Struyfs H, Goossens J, Niemantsverdriet E, Luyckx J, De Roeck N et al (2016) A decade of cerebrospinal fluid biomarkers for Alzheimer\u2019s disease in Belgium. J Alzheimer\u2019s Dis 54:383\u2013395","journal-title":"J Alzheimer\u2019s Dis"},{"key":"3107_CR66","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3233\/JAD-150167","volume":"49","author":"J Spiegel","year":"2015","unstructured":"Spiegel J, Pirraglia E, Osorio RS, Glodzik L, Li Y, Tsui W et al (2015) Greater Specificity for Cerebrospinal Fluid P-tau231 over P-tau181 in the Differentiation of Healthy Controls from Alzheimer\u2019s Disease. J Alzheimer\u2019s Dis 49:93\u2013100","journal-title":"J Alzheimer\u2019s Dis"},{"key":"3107_CR67","doi-asserted-by":"publisher","unstructured":"Spies PE, Claassen JAHR, Peer PGM, Blankenstein MA, Teunissen CE, Scheltens P et al (2013) A prediction model to calculate probability of Alzheimer\u2019s disease using cerebrospinal fluid biomarkers. Alzheimer\u2019s Dement [Internet]. 9:262\u20138. Available from: https:\/\/doi.org\/10.1016\/j.jalz.2012.01.010","DOI":"10.1016\/j.jalz.2012.01.010"},{"key":"3107_CR68","doi-asserted-by":"crossref","unstructured":"Struyfs H, Molinuevo JL, Martin JJ, De Deyn PP au., Engelborghs S (2014) Validation of the AD-CSF-index in autopsy-confirmed Alzheimer\u2019s disease patients and healthy controls. J Alzheimers Dis. 41:903\u20139","DOI":"10.3233\/JAD-131085"},{"key":"3107_CR69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fnagi.2022.963845","volume":"14","author":"Q Sun","year":"2022","unstructured":"Sun Q, Ni J, Wei M, Long S, Li T, Fan D et al (2022) Plasma \u03b2-amyloid, tau, neurodegeneration biomarkers and inflammatory factors of probable Alzheimer\u2019s disease dementia in Chinese individuals. Front Aging Neurosci 14:1\u201312","journal-title":"Front Aging Neurosci"},{"key":"3107_CR70","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1111\/j.1600-0404.2011.01592.x","volume":"125","author":"F Tabaraud","year":"2012","unstructured":"Tabaraud F, Leman JP, Milor AM, Roussie JM, Barri\u00e8re G, Tartary M et al (2012) Alzheimer CSF biomarkers in routine clinical setting. Acta Neurol Scand 125:416\u2013423","journal-title":"Acta Neurol Scand"},{"key":"3107_CR71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13024-017-0206-8","volume":"12","author":"H Tatebe","year":"2017","unstructured":"Tatebe H, Kasai T, Ohmichi T, Kishi Y, Kakeya T, Waragai M et al (2017) Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: Pilot case-control studies including patients with Alzheimer\u2019s disease and down syndrome. Mol Neurodegener 12:1\u201311","journal-title":"Mol Neurodegener"},{"key":"3107_CR72","doi-asserted-by":"publisher","first-page":"6456","DOI":"10.1002\/alz.14138","volume":"20","author":"P Thanapornsangsuth","year":"2024","unstructured":"Thanapornsangsuth P, Booncharoen K, Khieukhajee J, Luechaipanit W, Haethaisong T, Chongsuksantikul A et al (2024) The Bayesian approach for real-world implementation of plasma p-tau217 in tertiary care memory clinics in Thailand. Alzheimer\u2019s Dement 20:6456\u20136467","journal-title":"Alzheimer\u2019s Dement"},{"issue":"Suppl 1","key":"3107_CR73","first-page":"77","volume":"94","author":"J Thaweepoksomboon","year":"2011","unstructured":"Thaweepoksomboon J, Senanarong V, Poungvarin N, Chakorn T, Siwasariyanon N, Washirutmangkur L et al (2011) Assessment of cerebrospinal fluid (CSF) beta-amyloid (1\u201342), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer\u2019s disease (AD) and other dementia at Siriraj Hospital, Thailand. J Med Assoc Thai 94(Suppl 1):77\u201383","journal-title":"J Med Assoc Thai"},{"key":"3107_CR74","doi-asserted-by":"publisher","unstructured":"Tieu M, Van, Choi SH, Le HTN, Cho S (2023) Electrochemical impedance-based biosensor for label-free determination of plasma P-tau181 levels for clinically accurate diagnosis of mild cognitive impairment and Alzheimer\u2019s disease. Anal Chim Acta [Internet]. 1273:341535. Available from: https:\/\/doi.org\/10.1016\/j.aca.2023.341535","DOI":"10.1016\/j.aca.2023.341535"},{"key":"3107_CR75","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1515\/CCLM.2006.258","volume":"44","author":"H Vanderstichele","year":"2006","unstructured":"Vanderstichele H, De Vreese K, Blennow K, Andreasen N, Sindic C, Ivanoiu A et al (2006) Analytical performance and clinical utility of the INNOTEST\u00ae PHOSPHO-TAU(181P) assay for discrimination between Alzheimer\u2019s disease and dementia with Lewy bodies. Clin Chem Lab Med 44:1472\u20131480","journal-title":"Clin Chem Lab Med"},{"key":"3107_CR76","doi-asserted-by":"publisher","unstructured":"Li W, Sun L, Yue L, Xiao S (2024) Diagnostic and predictive power of plasma proteins in Alzheimer\u2019s disease: a cross-sectional and longitudinal study in China. Sci Rep [Internet]. 14:1\u201310. Available from: https:\/\/doi.org\/10.1038\/s41598-024-66195-7","DOI":"10.1038\/s41598-024-66195-7"},{"key":"3107_CR77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fnagi.2022.900773","volume":"14","author":"W Qin","year":"2022","unstructured":"Qin W, Li F, Jia L, Wang Q, Li Y, Wei Y et al (2022) Phosphorylated Tau 181 Serum Levels Predict Alzheimer\u2019s Disease in the Preclinical Stage. Front Aging Neurosci 14:1\u201311","journal-title":"Front Aging Neurosci"},{"key":"3107_CR78","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s00702-008-0177-6","volume":"116","author":"V Welge","year":"2009","unstructured":"Welge V, Fiege O, Lewczuk P, Mollenhauer B, Esselmann H, Klafki HW et al (2009) Combined CSF tau, p-tau181 and amyloid-\u03b2 38\/40\/42 for diagnosing Alzheimer\u2019s disease. J Neural Transm 116:203\u2013212","journal-title":"J Neural Transm"},{"key":"3107_CR79","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1093\/clinchem\/hvab192","volume":"67","author":"X Wu","year":"2021","unstructured":"Wu X, Xiao Z, Yi J, Ding S, Gu H, Wu W et al (2021) Development of a Plasma Biomarker Diagnostic Model Incorporating Ultrasensitive Digital Immunoassay as a Screening Strategy for Alzheimer Disease in a Chinese Population. Clin Chem 67:1628\u20131639","journal-title":"Clin Chem"},{"key":"3107_CR80","first-page":"1","volume":"16","author":"L Wu","year":"2023","unstructured":"Wu L, Arvai S, Wang SHJ, Liu AJ, Xu B (2023) Differential diagnosis of mild cognitive impairment of Alzheimer\u2019s disease by Simoa p-tau181 measurements with matching plasma and CSF. Front Mol Neurosci 16:1\u201311","journal-title":"Front Mol Neurosci"},{"key":"3107_CR81","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1159\/000320206","volume":"30","author":"I Yakushev","year":"2010","unstructured":"Yakushev I, Bartenstein P, Siessmeier T, Hiemke C, Scheurich A, Lotz J et al (2010) Cerebrospinal fluid tau protein levels and f-fluorodeoxyglucose positron emission tomography in the differential diagnosis of Alzheimer\u2019s disease. Dement Geriatr Cogn Disord 30:245\u2013253","journal-title":"Dement Geriatr Cogn Disord"},{"key":"3107_CR82","doi-asserted-by":"publisher","unstructured":"Patsopoulos NA, Evangelou E, Ioannidis JPA (2008) Sensitivity of between-study heterogeneity in meta-analysis: proposed metrics and empirical evaluation. Int J Epidemiol [Internet]. 37:1148\u201357. Available from: https:\/\/doi.org\/10.1093\/ije\/dyn065","DOI":"10.1093\/ije\/dyn065"},{"key":"3107_CR83","doi-asserted-by":"publisher","unstructured":"Janelidze S, Stomrud E, Smith R, Palmqvist S, Mattsson N, Airey DC et al (2020) Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer\u2019s disease. Nat Commun [Internet]. 11:1683. Available from: https:\/\/doi.org\/10.1038\/s41467-020-15436-0","DOI":"10.1038\/s41467-020-15436-0"},{"key":"3107_CR84","doi-asserted-by":"publisher","unstructured":"Lai R, Li B, Bishnoi R (2024) P-tau217 as a Reliable Blood-Based Marker of Alzheimer\u2019s Disease. Biomedicines [Internet]. 12. Available from: https:\/\/doi.org\/10.3390\/biomedicines12081836","DOI":"10.3390\/biomedicines12081836"},{"key":"3107_CR85","doi-asserted-by":"publisher","unstructured":"Dasari M, Kurian JA, Gundraju S, Raparthi A, Medapati RV (2025) Blood-Based \u03b2-Amyloid and Phosphorylated Tau (p-Tau) Biomarkers in Alzheimer\u2019s Disease: A Systematic Review of Their Diagnostic Potential. Cureus [Internet]. 17:e79881. Available from: https:\/\/doi.org\/10.7759\/cureus.79881","DOI":"10.7759\/cureus.79881"},{"key":"3107_CR86","doi-asserted-by":"publisher","unstructured":"Zabala-Findlay A, Penny LK, Lofthouse RA, Porter AJ, Palliyil S, Harrington CR et al (2023) Utility of Blood-Based Tau Biomarkers for Mild Cognitive Impairment and Alzheimer\u2019s Disease: Systematic Review and Meta-Analysis. Cells [Internet]. 12. Available from: https:\/\/doi.org\/10.3390\/cells12081184","DOI":"10.3390\/cells12081184"},{"key":"3107_CR87","unstructured":"WHO publishes preferred product characteristics for blood tests for Alzheimer disease [Internet] Available from: https:\/\/www.who.int\/news\/item\/23-10-2024-who-publishes-preferred-product-characteristics-for-blood-tests-for-alzheimer-disease"},{"key":"3107_CR88","doi-asserted-by":"publisher","unstructured":"Canestaro WJ, Bateman RJ, Holtzman DM, Monane M, Braunstein JB (2024) Use of a Blood Biomarker Test Improves Economic Utility in the Evaluation of Older Patients Presenting with Cognitive Impairment. Popul Health Manag [Internet]. 27:174\u201384. Available from: https:\/\/doi.org\/10.1089\/pop.2023.0309","DOI":"10.1089\/pop.2023.0309"}],"container-title":["Acta Neurologica Belgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-026-03107-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13760-026-03107-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-026-03107-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T02:59:02Z","timestamp":1793156342000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13760-026-03107-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":88,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["3107"],"URL":"https:\/\/doi.org\/10.1007\/s13760-026-03107-8","relation":{},"ISSN":["0300-9009","2240-2993"],"issn-type":[{"value":"0300-9009","type":"print"},{"value":"2240-2993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"assertion":[{"value":"2 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"<b>Consent for publication<\/b>","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Our manuscript was not applied to human beings and thus requires no ethical approval.","order":3,"name":"Ethics","label":"Human ethics and consent to participate statement","group":{"name":"EthicsHeading","label":"Declarations"}}]}}